No registrations found.
ID
Source
Brief title
Health condition
obesity
nafld-nash
bariatric surgery
Sponsors and support
Intervention
Outcome measures
Primary outcome
To identify microbial, immunological and metabolic markers associated with weightloss after bariatric surgery. To this end, we will collect before, during surgery and after 2 years follow up.
Secondary outcome
To apply systems biology approach to identify hierarchy of driving mechanisms (microbial, immunological and metabolic markers) in relation to diet and satiety involved in the long term beneficial weight loss effects of bariatric surgery that can be used for personalised medicine
Study objective
It is increasingly recognized that the immune system is a major player in this obesity related disease and the switch from benign to malign (insulin resistance and DM2) obesity is associated with changes in the immune system . In this regard, animal studies have suggested that the intestinal microbiome is thought to play a major role in driving these immunological and metabolites changes. However, at this moment it is unknown whether and to what extend intestinal microbiota and immunological tone can predict metabolic response (improvement in insulin sensitivity and weightloss) upon bariatric surgery. Increased understanding of the pathophysiological mechanism as well as their relationship to metabolic disturbances are thought to be of crucial importance to discover new diagnostic and therapeutical targets in obesity associated insulin resistance and NAFLD/NASH. Moreover, this study will identify the underlying pathophysiological mechanisms in subjects that will have NAFLD/NASH reduction upon the surgery (responders) and those that have no beneficial effect on at all (non-responders). This might help to predict who will benefit from the surgical intervention and in whom this is not effective.
Study design
0,1,2,12 and 24 months
Intervention
bariatric surgery
MEIBERGDREEF 9, KAMER F4.159.2
M. Nieuwdorp
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666612
m.nieuwdorp@amc.uva.nl
MEIBERGDREEF 9, KAMER F4.159.2
M. Nieuwdorp
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666612
m.nieuwdorp@amc.uva.nl
Inclusion criteria
- Scheduled for bariatric surgery
- Ability to provide informed consent
- No more than 5% weight loss in 6 months prior to surgery
- No more than 3% weight loss in 1 month prior to surgery
Exclusion criteria
- Known genetic basis for insulin resistance or glucose intolerance
- All medical and psychiatric conditions except for obesity related diseases.
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL5837 |
NTR-old | NTR5992 |
Other | : METC 2015_357 |